company background image
APVO logo

Aptevo Therapeutics NasdaqCM:APVO Stock Report

Last Price

US$4.41

Market Cap

US$2.2m

7D

13.7%

1Y

-98.6%

Updated

23 Dec, 2024

Data

Company Financials +

Aptevo Therapeutics Inc.

NasdaqCM:APVO Stock Report

Market Cap: US$2.2m

APVO Stock Overview

A clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. More details

APVO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Aptevo Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Aptevo Therapeutics
Historical stock prices
Current Share PriceUS$4.41
52 Week HighUS$399.60
52 Week LowUS$3.65
Beta5.01
1 Month Change-61.26%
3 Month Change-31.30%
1 Year Change-98.58%
3 Year Change-99.96%
5 Year Change-99.97%
Change since IPO-99.99%

Recent News & Updates

Recent updates

Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy

Sep 19

Aptevo meets primary endpoint in early-stage trial for blood cancer therapy

May 26

Aptevo: Positive Early Stage Data Makes This Highly Interesting

Dec 02

Aptevo gets $50/share takeout offer from shareholder Tang

Nov 18

Aptevo Therapeutics rallies 113% as Tang Capital discloses 54% stake

Nov 09

Aptevo sells off after clarifying complete response in early-stage study on lead drug

Nov 05

Shareholder Returns

APVOUS BiotechsUS Market
7D13.7%-3.8%-2.7%
1Y-98.6%-2.6%23.4%

Return vs Industry: APVO underperformed the US Biotechs industry which returned -2.6% over the past year.

Return vs Market: APVO underperformed the US Market which returned 23.4% over the past year.

Price Volatility

Is APVO's price volatile compared to industry and market?
APVO volatility
APVO Average Weekly Movement29.6%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: APVO's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: APVO's weekly volatility (29%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201640Marvin Whitewww.aptevotherapeutics.com

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company’s lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia.

Aptevo Therapeutics Inc. Fundamentals Summary

How do Aptevo Therapeutics's earnings and revenue compare to its market cap?
APVO fundamental statistics
Market capUS$2.21m
Earnings (TTM)-US$24.01m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
APVO income statement (TTM)
RevenueUS$0
Cost of RevenueUS$16.89m
Gross Profit-US$16.89m
Other ExpensesUS$7.13m
Earnings-US$24.01m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-48.00
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did APVO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 22:12
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aptevo Therapeutics Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wangzhi LiLadenburg Thalmann & Company
Edward TenthoffPiper Sandler Companies
Jonathan AschoffRoth MKM